Rationale for use of type I interferons as the effector moiety: Over the past several decades, IFN-Is have proven to be safe and effective as FDA-approved biologics for a broad spectrum of disease classes, including cancer, infectious diseases (e.g., hepatitis B and C), and autoimmune diseases (e.g., multiple sclerosis) [44,45,46,47]. The gene discussed is IFNA1; the disease is cancer.